6 days ago
Bowel cancer “melted away” after immunotherapy, then stayed away
What's happening
SignalsMonitor is following this as a technology story. ScienceDaily Top News and ScienceDaily Health are the outlets attached to this story. The first report grouped here was at 10 Oct 2026, 18:42 UTC. 2 material updates are listed in the timeline. The headline in use is “Bowel cancer “melted away” after immunotherapy, then stayed away”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by ScienceDaily Top News
Bowel cancer “melted away” after immunotherapy, then stayed away
- Picked up by ScienceDaily Health
Bowel cancer “melted away” after immunotherapy, then stayed away
Same story, different outlets
2 headlinesEach line is that outlet's headline. The article stays on the publisher's site.
- ScienceDaily HealthBowel cancer “melted away” after immunotherapy, then stayed away
- ScienceDaily Top NewsBowel cancer “melted away” after immunotherapy, then stayed away